Moreover, Glypican-3, a heparin-sulfate proteoglycan recently reported to show a high degree of specificity for HCC versus benign hepatocellular proliferations, is limited by its relatively low sensitivity [33,36]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.